NCT03044587 · CITED IN SOURCE DOCUMENTS

Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2025-10-01

AIO-YMO/HEP-0315 (NIFE) is an open label, non-comparative, randomized, multicenter phase II trial

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part

eligibility Criteria: Inclusion Criteria: 1. Written informed consent incl. participation in translational research and any locally-required authorization (EU Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations 2. Age ≥ 18 years at time of study entry 3. Histologically confirmed, non-resectable, locally advanced or metastatic adenocarcinoma of the intrahepatic or extrahepatic biliary tract 4. Protocol-specific staging guidelines have to be observed and non-resectability has to be confirmed by local tumor board 5. Measurable or assessable disease according to RECIST 1.1 6. ECOG performance status 0-1 7. Life expectancy of more than 3 months 8. If applicable, adequately treated biliary tract obstruction before study entry with total bilirubin concentration ≤ 2 x ULN 9. Adequate blood count, liver-enzymes, and renal function: * White blood cell count ≥ 3.5 x 10\^6/mL * Platelet count ≥ 100 x 10\^9/L (\>100,000 per mm3) * AST (SGOT)/ALT (SGPT) ≤ 5 x institutional upper limit of normal * Serum Creatinine ≤ 1.5 x ULN and a calculated glomerular filtration rate ≥ 30 mL per minute 10. Patients not receiving therapeutic anticoagulation must have an INR \< 1.5 ULN and PTT \< 1.5 ULN within 7 days prior to randomization. The use of full dose anticoagulants is allowed as long as the INR or PTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least three weeks at the time of randomization 11. No prior palliative chemotherapy for biliary tract cancer 12. No adjuvant treatment within 6 months prior to study entry 13. Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up. Exclusion Criteria: 1. Active uncontrolled infection, chronic infectious diseases, immune deficiency syndromes 2. Premalignant hematologic disorders, e.g. myelodysplastic syndrome 3. Clinically significant cardiovascular disease (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) within 6 months before enrollment 4. Prior (\>5 years) or concurrent malignancy (other than biliary-tract cancer) which either progresses or requires active treatment. Exceptions are: basal cell cancer of the skin, pre-invasive cancer of the cervix, T1a or T1b prostate carcinoma, or superficial bladder tumor \[Ta, Tis and T1\]. 5. Pre-existing lung disease 6. History or clinical evidence of CNS metastases Exceptions are: Subjects who have completed local therapy and who meet both of the following criteria: 1. are asymptomatic and 2. have no requirement for steroids 6 weeks prior to start of study treatment. Screening with CNS imaging (CT or MRI) is required only if clinically indicated or if the subject has a history of CNS metastases 7. History of hypersensitivity to any of the study drugs or any of the constituents of the products 8. Allogeneic transplantation requiring immunosuppressive therapy or other major immunosuppressive therapy 9. Severe non-healing wounds, ulcers or bone fractions 10. Evidence of bleeding diathesis or coagulopathy 11. Major surgical procedures, except open biopsy, nor significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgical procedure during the course of the study except for surgery of central intravenous line placement for chemotherapy administration. 12. Medication that is known to interfere with any of the agents applied in the trial. 13. Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year). \[Acceptable methods of contraception are: implants, injectable contraceptives, combined oral contraceptives, intrauterine pessary (only hormonal devices), sexual abstinence or vasectomy of the partner\]. Women of childbearing potential must have a negative pregnancy test (serum β-HCG) at Screening. 14. Known Gilbert-Meulengracht syndrome 15. Known chronic hypoacusis, tinnitus or vertigo 16. Any condition or comorbidity that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results 17. Participation in another clinical study with an investigational product during the last 30 days before inclusion or 7 half-lifes of previously used trial medication, whichever is of longer duration. 18. Previous enrollment or randomization in the present study (does not include screening failure). 19. Any other chemotherapy at study start 20. Involvement in the planning and/or conduct of the study 21. Patient who might be dependent on the sponsor, site or the investigator 22. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities. 23. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts.
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Nal-IRI \[Irinotecan liposome\], 5-FU \[5-Fluorouracil\], Leucovorin Cycle q2w
intervention Names
Drug: Arm NaI-IRI + 5-FU + Leucovorin (Arm A)
label
Arm NaI-IRI + 5-FU + Leucovorin (Arm A)
type
EXPERIMENTAL
description
Cisplatin, Gemcitabine Cycle q3w
intervention Names
Drug: Arm Cisplatin + Gemcitabine (Arm B)
label
Arm Cisplatin + Gemcitabine (Arm B, standard of care)
type
OTHER

interventions

arm Group Labels
Arm NaI-IRI + 5-FU + Leucovorin (Arm A)
description
Nal-IRI (80 mg/m2 as a 1.5 hour infusion), 5-FU (2400 mg/m2 as 46 hour infusion) and Leucovorin (400 mg/m2 as 0.5 hour infusion) Cycle q2w
name
Arm NaI-IRI + 5-FU + Leucovorin (Arm A)
type
DRUG
arm Group Labels
Arm Cisplatin + Gemcitabine (Arm B, standard of care)
description
Cisplatin (25 mg/m2 as 1 hour infusion on D1, D8) and Gemcitabine (1000 mg/m2 as 0.5 hour infusion on D1, D8) Cycle q3w
name
Arm Cisplatin + Gemcitabine (Arm B)
type
DRUG

Study design

allocation

RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 93
type: ACTUAL

Registered outcome plans (not posted results)

other Outcomes

description
cfDNA exome sequencing, transcriptome, miRNA-arrays prior to and after start of treatment and upon progress
measure
Exploratory biomarkers analysis
time Frame
approx. 54 months
measure
Establishment of Predictive/Prognostic biomarker profiles for advanced cholangiocarcinoma
time Frame
approx. 54 months
measure
Tumor Evolution under systemic therapy
time Frame
approx. 54 months

primary Outcomes

measure
Progression-free survival [PFS]
time Frame
approx. 25 months

secondary Outcomes

description
Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)
measure
Overall progression free survival according to RECIST 1.1
time Frame
approx. 54 months
description
3-years overall survival
measure
3-years overall survival
time Frame
approx. 36 months
measure
Disease control rate according to RECIST 1.1
time Frame
approx. 54 months
description
Proportion of patients with an objective response according to RECIST 1.1
measure
Objective tumor response rate (ORR) according to RECIST 1.1
time Frame
approx. 54 months
measure
Toxicity/Safety according to CTC-AE-criteria
time Frame
approx. 54 months
description
EORTC QLQ-BIL21
measure
Health related quality of life
time Frame
approx. 54 months
description
EORTC QLQ-C30
measure
Health related quality of life
time Frame
approx. 54 months
description
Hospital Anxiety and Depression Scale (HADS-D)
measure
Health related quality of life
time Frame
approx. 54 months
description
Tumor resectability in accordance with a retrospective central surgical board compared to local surgical review
measure
Retrospective correlation of resectability in accordance with a central surgical board compared to local surgical review
time Frame
approx. 54 months
measure
Retrospective central radiological review
time Frame
approx. 54 months

Full study description

brief Summary: AIO-YMO/HEP-0315 (NIFE) is an open label, non-comparative, randomized, multicenter phase II trial
detailed Description: The primary objective is to determine whether a combination of 5-FU and nal-IRI prolongs progression-free survival in patients with locally advanced or metastatic adenocarcinoma of the biliary tract

Source references

references

citation
Ettrich TJ, Modest DP, Sinn M, Striefler JK, Opitz B, Goetze T, Gallmeier E, Angermeier S, Fischer von Weikersthal L, Jacobasch L, Waldschmidt D, Niedermeier M, Sohm M, Berger AW, Manzini G, Fehrenbach U, Auer TA, Hosse C, Vogele D, Sookthai D, Schaaf M, Muche R, Hinke A, Seufferlein T, Perkhofer L. Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315). J Clin Oncol. 2024 Sep 10;42(26):3094-3104. doi: 10.1200/JCO.23.01566. Epub 2024 Jun 6.
pmid
38843469
type
DERIVED
citation
Perkhofer L, Berger AW, Beutel AK, Gallmeier E, Angermeier S, Fischer von Weikersthal L, Goetze TO, Muche R, Seufferlein T, Ettrich TJ. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study. BMC Cancer. 2019 Oct 23;19(1):990. doi: 10.1186/s12885-019-6142-y.
pmid
31646981
type
DERIVED